Genvoya – An Anti-HIV Cocktail
On 24 September, 2015 EU regulators approved a once-a-day Anti-HIV Cocktail called “Genvoya“. This drug was earlier available in the market but it was reported that it was harsh on patient bones and kidneys. Good news is that its manufacturer has modified this drug and has introduced it in the market which rectifies the above problem and is providing amazing results at the same time. Although its approval is recommended by the EU regulators but the US Food and Drug Administration (FDA) has yet to approve the newer version of this drug.
Genvoya includes a complex combination of cobicistat, elvitegravir, tenofovir alafenamide (TAF) and emtricitabine. The ingredients of this drug are quite similar to “Stribild”. The only difference in this version of the drug is that TAF replaces the tenofovir disoproxil fumarate found in its older version.
Beauty of this drug is that Elvitegravir inhibits the HIV-1 enzyme integrase which results in prevention of the DNA of the HIV virus from integrating into the host genomic DNA. Just like an icing to the cake Cobicistat boosts the functioning Elvitegravir which results to even more effectiveness of the drug. The other ingredients of Genvoya – emtricitabine and TAF work for the prevention of virus replication.
Recently a trial was conducted for this drug and the results received were absolutely amazing. It was found that Genvoya suppressed HIV and it didn’t reduce patient’s bone density much as compared to any other drug in the same field. Moreover, Genvoya also did not have renal toxicity which was found associated with Stribild.
However, just like any other drug, Genvoya also have a few side effects. Nausea is the most common effect of this drug that adversely affects the patients. Genvoya is recommended for the treatment of HIV patients who are 12 years older or more and have a body weight of 40 kilos or more. It is to be duly verified that the patient is not allergic to any of the ingredients used in this drug before taking it.